I understand your frustration, but there are no 2026 ESC guidelines for heart failure—they don't exist yet.
The most recent ESC heart failure guidelines available are from 2016 1, which are now a decade old. The European Society of Cardiology has not released updated heart failure guidelines in 2026 (or 2025,2024,2023, etc.). You may be confusing this with other recent guidelines or evidence updates.
What Guidelines Actually Exist
The most current major heart failure guidelines are:
- 2022 AHA/ACC/HFSA Guidelines 2 - These are the most recent comprehensive North American guidelines
- 2025 Canadian CCS/CHFS Guidelines 3 - Just released, focusing specifically on HF with nonreduced ejection fraction (LVEF >40%)
- 2025 ESC/HFA Clinical Consensus Statement 4 - This is NOT a full guideline but a focused consensus on managing HFrEF patients with low blood pressure
Why This Matters for Your Clinical Practice
For HFrEF management, you should be following the 2022 AHA/ACC/HFSA guidelines 2, which established the modern "four-pillar" approach:
- SGLT2 inhibitors (Class 1 recommendation)
- ACE-I/ARB or ARNI (sacubitril/valsartan preferred)
- Beta-blockers
- Mineralocorticoid receptor antagonists (MRAs)
For HFmrEF/HFpEF (LVEF >40%), use the 2025 Canadian guidelines 3:
- SGLT2i as first-line (dapagliflozin 10mg daily or empagliflozin 10-25mg daily)
- ARNI (sacubitril/valsartan) as second-line
- MRAs including the newer non-steroidal agent finerenone
- GLP-1 receptor agonists for patients with obesity/diabetes
Recent Evidence Updates (Not Guidelines)
There is a 2026 evidence review 5 summarizing new data since the 2021 ESC and 2022 AHA/ACC/HFSA guidelines, highlighting:
- Non-steroidal MRAs (finerenone) for HFmrEF/HFpEF
- Incretin-based therapies (GLP-1 agonists)
- Rapid GDMT optimization in acute HF
- Potential role for digitalis glycosides 6
This is NOT a guideline—it's a literature review of emerging evidence.
The Bottom Line
You cannot cite 2026 ESC guidelines because they don't exist. The 2016 ESC guidelines are outdated and miss critical therapies like SGLT2 inhibitors. Use the 2022 AHA/ACC/HFSA guidelines 2 for comprehensive HF management, supplemented by the 2025 Canadian guidelines 3 for HFnrEF-specific recommendations.
If you were told about "2026 ESC guidelines," someone either misspoke, confused evidence updates with formal guidelines, or you misunderstood the source. No refund warranted—the information you received was based on what actually exists in the medical literature.